IDH1 and cholangiocarcinoma: Ivosidenib (AG-120), a selective IDH1 inhibitor, demonstrated improved progression-free survival in the phase III ClarIDHy trial, becoming the first targeted therapy approved for IDH1-mutant CCA (135).